Skip to main content

Table 1 Demographic and baseline characteristics (safety population) by last dose in the dose-optimization phase

From: Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design

Characteristic, mean (SD) LDX
30 mg/d
(n = 28)
LDX
50 mg/d
(n = 70)
LDX
70 mg/d
(n = 44)
LDX
All Doses
(N = 142)
Age (years) 30.5 (9.54) 29.7 (10.71) 31.8 (11.46) 30.5 (10.70)
Weight (lb) 174.7 (43.64) 176.7 (35.22) 182.4 (36.17) 178.1 (37.14)
Height (in) 65.8 (4.30) 68.3 (3.73) 68.3 (3.77) 67.8 (3.97)
Body mass index (lb/in2) 28.2 (5.45) 26.6 (4.79) 27.4 (5.10) 27.2 (5.02)
Gender, n(%)     
   Male/female 16 (57.1)/12 (42.9) 45 (64.3)/25 (35.7) 27 (61.4)/17 (38.6) 88 (62.0)/54 (38.0)
Race, n (%)
   White 21 (75.0) 65 (92.9) 41 (93.2) 127 (89.4)
   Black/African American 4 (14.3) 2 (2.9) 0 6 (4.2)
   Native Hawaiian/Pacific Islander 2 (7.1) 0 0 2 (1.4)
   Asian 1 (3.6) 2 (2.9) 2 (4.5) 5 (3.5)
   American Indian/Alaskan Native 0 0 1 (2.3) 1 (0.7)
   Other 0 1 (1.4) 0 1 (0.7)
Ethnicity, n (%)
Hispanic or Latino/
Not Hispanic or Latino
2 (7.1)/26 (92.9) 7 (10.0)/63 (90.0) 4 (9.1)/40 (90.9) 13 (9.2)/129 (90.8)
ADHD subtype, n (%)
   Inattentive 8 (28.6) 20 (28.6) 11 (25.0) 39 (27.5)
   Hyperactive/impulsive 1 (3.6) 3 (4.3) 1 (2.3) 5 (3.5)
   Combined 19 (67.9) 47 (67.1) 32 (72.7) 98 (69.0)
ADHD-RS-IV with adult prompts: scores at baseline, mean (SD)     
   Total 37.8 (6.06) 35.8 (4.85) 38.4 (6.12) 37.0 (5.61)
   Inattentive 20.9 (3.15) 19.7 (3.45) 20.8 (3.66) 20.3 (3.49)
   Hyperactivity/impulsivity 16.9 (5.52) 16.1 (4.35) 17.6 (4.86) 16.7 (4.77)
  1. ADHD = attention-deficit/hyperactivity disorder; ADHD-RS-IV = ADHD Rating Scale IV; LDX = lisdexamfetamine dimesylate.